The estimated Net Worth of Lai Wang is at least $301 Миллион dollars as of 17 May 2022. Mr Wang owns over 1,233,947 units of BeiGene Ltd stock worth over $297,404,353 and over the last 3 years he sold BGNE stock worth over $2,106,157. In addition, he makes $1,128,165 as Global Head of R&D at BeiGene Ltd.
Mr has made over 12 trades of the BeiGene Ltd stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,064 units of BGNE stock worth $170,027 on 24 June 2024.
The largest trade he's ever made was exercising 1,233,947 units of BeiGene Ltd stock on 17 May 2022 worth over $4,022,667. On average, Mr trades about 82,963 units every 74 days since 2021. As of 17 May 2022 he still owns at least 1,408,498 units of BeiGene Ltd stock.
You can see the complete history of Mr Wang stock trades at the bottom of the page.
Wang Lai is the Global Head of R&D at BeiGene Ltd.
As the Global Head of R&D of BeiGene Ltd, the total compensation of Mr Lai at BeiGene Ltd is $1,128,165. There are 5 executives at BeiGene Ltd getting paid more, with John Oyler having the highest compensation of $13,899,000.
Mr Lai is 44, he's been the Global Head of R&D of BeiGene Ltd since . There are 21 older and no younger executives at BeiGene Ltd. The oldest executive at BeiGene Ltd is Donald Glazer, 75, who is the Non-Executive Independent Director.
Lai's mailing address filed with the SEC is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108.
Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd.... и Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
BeiGene Ltd executives and other stock owners filed with the SEC include: